Detected ·
Nouscom
€120MSeries D
Nouscom announced an oversubscribed €120M ($135M) Series D financing, co-led by M Ventures and Revelation Partners, to advance NOUS-209 into a pivotal trial for cancer interception in Lynch syndrome.
- Website
- —
- linkedin.com/company/18328527
- Amount
- €120 000 000 EUR
- Stage
- Series D
- Event
- Funding round
- Detected
- 2026-10-20 08:06:12 UTC
- Signal ID
- fcedf948-4b71-45cb-9653-ec292195ad87
As the API returns it
{
"id": "fcedf948-4b71-45cb-9653-ec292195ad87",
"created_at": "2026-10-20T08:06:12.642268Z",
"company_name": "Nouscom",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/18328527",
"event_type": "funding",
"funding_amount": 120000000,
"funding_currency": "EUR",
"funding_stage": "series_d",
"message": "*Nouscom announced an oversubscribed €120M ($135M) Series D financing, co-led by M Ventures and Revelation Partners, to advance NOUS-209 into a pivotal trial for cancer interception in Lynch syndrome.*"
}